Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessio Ciulli

Showing results (101-110 of 148) with videos related to

Pageof 15
Sort By:
Molecular Biosystems|August 2, 2011
Bromodomain-peptide displacement assays for interactome mapping and inhibitor discoveryMartin Philpott, Jing Yang, Tony Tumber, et al.
Journal of Medicinal Chemistry|December 6, 2013
Targeting low-druggability bromodomains: fragment based screening and inhibitor design against the BAZ2B bromodomainFleur M Ferguson, Oleg Fedorov, Apirat Chaikuad, et al.
Journal of Medicinal Chemistry|September 14, 2023
Expanding the Structural Diversity at the Phenylene Core of Ligands for the von Hippel-Lindau E3 Ubiquitin Ligase: Development of Highly Potent Hypoxia-Inducible Factor-1α StabilizersLan Phuong Vu, Claudia J Diehl, Ryan Casement, et al.
Chemmedchem|June 11, 2021
The 2<sup>nd</sup> Alpine Winter Conference on Medicinal and Synthetic ChemistryAlessio Ciulli, Lawrence Hamann, Wolfgang Jahnke, et al.
Chemmedchem|August 30, 2022
Discovery of Benzo[d]imidazole-6-sulfonamides as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the First BromodomainAlessandra Cipriano, Ciro Milite, Alessandra Feoli, et al.
Journal of the American Chemical Society|November 28, 2024
Leveraging Dual-Ligase Recruitment to Enhance Protein Degradation via a Heterotrivalent Proteolysis Targeting ChimeraAdam G Bond, Miquel Muñoz I Ordoño, Celia M Bisbach, et al.
The Biochemical Journal|March 18, 2011
Structural investigation of inhibitor designs targeting 3-dehydroquinate dehydratase from the shikimate pathway of Mycobacterium tuberculosisMarcio V B Dias, William C Snee, Karen M Bromfield, et al.
Journal of the American Chemical Society|August 25, 2022
Discovery of XL01126: A Potent, Fast, Cooperative, Selective, Orally Bioavailable, and Blood-Brain Barrier Penetrant PROTAC Degrader of Leucine-Rich Repeat Kinase 2Xingui Liu, Alexia F Kalogeropulou, Sofia Domingos, et al.
Cell Chemical Biology|January 4, 2025
The efflux pump ABCC1/MRP1 constitutively restricts PROTAC sensitivity in cancer cellsGernot Wolf, Conner Craigon, Shao Thing Teoh, et al.
Exploration of Targeted Anti-Tumor Therapy|September 1, 2022
The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like typeChiara Tarantelli, Eleonora Cannas, Hillarie Ekeh, et al.
Pageof 15

Showing results (101-110 of 148) with videos related to

Sort By:
Pageof 15
Molecular Biosystems|August 2, 2011
Bromodomain-peptide displacement assays for interactome mapping and inhibitor discoveryMartin Philpott, Jing Yang, Tony Tumber, et al.
Journal of Medicinal Chemistry|December 6, 2013
Targeting low-druggability bromodomains: fragment based screening and inhibitor design against the BAZ2B bromodomainFleur M Ferguson, Oleg Fedorov, Apirat Chaikuad, et al.
Journal of Medicinal Chemistry|September 14, 2023
Expanding the Structural Diversity at the Phenylene Core of Ligands for the von Hippel-Lindau E3 Ubiquitin Ligase: Development of Highly Potent Hypoxia-Inducible Factor-1α StabilizersLan Phuong Vu, Claudia J Diehl, Ryan Casement, et al.
Chemmedchem|June 11, 2021
The 2<sup>nd</sup> Alpine Winter Conference on Medicinal and Synthetic ChemistryAlessio Ciulli, Lawrence Hamann, Wolfgang Jahnke, et al.
Chemmedchem|August 30, 2022
Discovery of Benzo[d]imidazole-6-sulfonamides as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the First BromodomainAlessandra Cipriano, Ciro Milite, Alessandra Feoli, et al.
Journal of the American Chemical Society|November 28, 2024
Leveraging Dual-Ligase Recruitment to Enhance Protein Degradation via a Heterotrivalent Proteolysis Targeting ChimeraAdam G Bond, Miquel Muñoz I Ordoño, Celia M Bisbach, et al.
The Biochemical Journal|March 18, 2011
Structural investigation of inhibitor designs targeting 3-dehydroquinate dehydratase from the shikimate pathway of Mycobacterium tuberculosisMarcio V B Dias, William C Snee, Karen M Bromfield, et al.
Journal of the American Chemical Society|August 25, 2022
Discovery of XL01126: A Potent, Fast, Cooperative, Selective, Orally Bioavailable, and Blood-Brain Barrier Penetrant PROTAC Degrader of Leucine-Rich Repeat Kinase 2Xingui Liu, Alexia F Kalogeropulou, Sofia Domingos, et al.
Cell Chemical Biology|January 4, 2025
The efflux pump ABCC1/MRP1 constitutively restricts PROTAC sensitivity in cancer cellsGernot Wolf, Conner Craigon, Shao Thing Teoh, et al.
Exploration of Targeted Anti-Tumor Therapy|September 1, 2022
The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like typeChiara Tarantelli, Eleonora Cannas, Hillarie Ekeh, et al.
Pageof 15